ABIVAX recently unveiled a significant financial maneuver, confirming a $90 million pact to reclaim and eliminate all royalty certificates that were initially distributed in September 2022. This decisive action underscores the company's commitment to fortifying its financial framework and eradicating any lingering royalty burdens. The initiative is set to pave the way for accelerated commercialization endeavors in the near future. The arrangement involves a dual funding approach, comprising a cash component and an issuance of ordinary shares, ingeniously structured to ensure negligible dilution for current investors.

This strategic financial adjustment is poised to finalize around May 7, contingent upon the successful fulfillment of standard closing conditions. Even with a substantial cash expenditure of $45 million, ABIVAX assures stakeholders that its financial liquidity remains strong, projecting its cash reserves to comfortably extend into the fourth quarter of 2027. This robust financial standing, bolstered by a significant reserve of €530.4 million in cash and cash equivalents as reported in late 2025, is critical for advancing the company's vital clinical programs and meticulously planned pre-commercial activities. ABIVAX continues to focus on developing advanced therapies for chronic inflammatory conditions, solidifying its position as a key player in the biotechnology sector.

This proactive step by ABIVAX not only enhances its financial stability but also demonstrates a forward-thinking approach to corporate governance and strategic growth. By optimizing its capital structure and removing potential future liabilities, the company is better positioned to invest in innovation, expand its market reach, and ultimately deliver greater value to patients and shareholders alike. This move is a testament to strong leadership and a clear vision for sustainable success in the competitive pharmaceutical landscape.